THE VIABILITY OF STEROIDS WITHIN THE TREATMENT OF BRONCHIOLITIS

Objective: To decide the viability of steroids within the treatment of bronchiolitis.

Patients and Methods: We carried out this randomized control trial at Sir Ganga Ram Hospital, Lahore from March 2018 to September 2018. Ninety patients of bronchiolitis were inspected and arbitrarily partitioned into three groups. Each group was given the same treatment convention varying as it were within the steroid given (Group I - intravenous Hydrocortisone, Group II – nebulized Beclomethasone, Group III - no steroids). Information was compiled by implies of a proforma. Results were the length of healing centre remain (LOS), distinction in the clinical respiratory score (R), and time to end up wheeze free (W).

Results: Cruel LOS was most reduced in Group II (p = 0.259). The cruel term ended up wheeze free (W) was too least in Group II (p= 0.40). The greatest change in Respiratory Trouble Evaluation Instrument (RDAI) score at affirmation and release (R) was in Group I and the slightest change in Group II (p=0.056).

Conclusions: Corticosteroids are not significantly effective in reducing the length of hospital stay, duration of wheezing and improvement in clinical severity. However, inhaled steroids may possibly have a potential advantage over parenteral steroids.

Keywords: Bronchiolitis, Beclomethasone nebulizer, steroids.